Disclosure of Transfers of Value to Healthcare Professionals and Healthcare Organisations

The pharmaceutical industry’s role in society is fundamental in bringing medicines to patients via a collaborative effort with healthcare professionals and healthcare organisations. The working relationship delivers innovation in medicine which is reliant upon the exchange of ideas and information with industry and healthcare professionals. Industry fulfils a vital role in providing medical education to healthcare professionals to ensure that they are updated on medical advancements to improve patient treatment and care. It is important to maintain confidence in the relationship between industry and healthcare professionals by being transparent about our activities.

Commitment to Transparency

Teva Ireland endorses the European Federation of Pharmaceutical Industries and Association’s (EFPIA) work in increasing transparency across the pharmaceutical industry. We are committed to being transparent about our transfer of value i.e. payments or benefit in kind made to healthcare professionals and healthcare organisations by publicly disclosing the information. The transfer of value results from collaborations with healthcare professionals and healthcare organisations in advisory boards, medical education, grants, clinical research and joint working projects to support patient care.

We take the disclosure effort seriously and encourage the healthcare professionals that we work with to provide consent to named disclosure. As a result,  we received 100% consent rate for 2017 disclosure data which fully comply with the Data Protection Acts (1988 and 2003) and the IPHA Code. The General Data Protection Regulation (GDPR) 2018 sets out new standards for obtaining consents which are different to the previous standard. To manage risk related to historic disclosures of individuals transfers of value, companies have the option to either re-consent to GDPR standards or put HCP details into aggregate (anonymous) reporting.

Teva Ireland has therefore reluctantly taken the decision to entirely aggregate the 2017 individual data and submit it without naming any of the healthcare professionals and decision makers. This decision was not made lightly, since we wholeheartedly support the pharmaceutical industry’s drive towards transparency.

Consent will be gathered in accordance with GDPR standard for future activities and we look forward to disclosing the data in due course.

Teva Ireland’s Transfer of Value disclosure


Step 1: Review the methodological note here, which relates to Teva Ireland’s Transfer of Value disclosure.

Step 2: Access Teva Ireland’s Transfer of Value disclosure here.

For any queries related to the disclosure data, please send an email to info@teva.ie

Date of preparation: June 2018

Ref: IE/CPE/18/0006